ProMab Biotechnologies, Inc.
Promab has over 15 years monoclonal antibody development expertise, and has
a portfolio of more than 1700 commercial monoclonal antibodies, targeting tumor antigens, intracellular proteins, cancer stem cell markers and circulating tumor cell markers. Promab has a new custom Chimeric Antigen Receptor-T (CAR-T) cell service and product development programs that are designed for pre-clinical and future clinical applications.
ProMab applies its proprietary proteins, antibodies and CAR-T cells to deliver innovative diagnostic products as well as services targeting the global biomedical market.